Jones, Nyasia M.
Yang, Hua
Zhang, Qing
Morales-Tirado, Vanessa M.
Grossniklaus, Hans E.
Funding for this research was provided by:
National Institutes of Health (NIH R01CA176001)
Foundation for the National Institutes of Health (NIH P30EY06360)
Researh to Prevent Blindness
Gerwin Fellowship
930 Friends
Article History
Received: 14 February 2018
Accepted: 14 May 2019
First Online: 22 May 2019
Authors’ information
: HY is an Associate Professor at the Research Section of the Department of Ophthalmology at Emory University, who focuses on anti-angiogenic and immune modulatory therapies against metastatic uveal melanoma. VMT is an Assistant Professor at the Departments of Ophthalmology and Microbiology, Immunology and Biochemistry (MIB) at the University of Tennessee Health Science Center. She leads the Ocular Oncology and Immunology Translational Research Unit at UTHSC and has expertise in human tumor immunology, intraocular tumors and pre-clinical models of disease. HEG serves as the Interim Vice Chair at the Emory Eye Center, founding director of the Ocular Oncology and Pathology Service and Director of the L.F. Montgomery Laboratory at Emory. HEG is considered an international expert in diagnostic ophthalmic pathology, and ocular oncology with over 500 publications in peer reviewed journals, over 25 book chapters and edited 10 books.
: This study was approved by the Emory University School of Medicine Institutional Animal Care and Utilization Committee (IACUC).
: Not applicable
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.